These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27471683)

  • 21. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
    Tang T; Eldabaje R; Yang L
    Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
    Khattak M; Fisher R; Turajlic S; Larkin J
    Ther Adv Med Oncol; 2013 Mar; 5(2):105-18. PubMed ID: 23450149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.
    Shahabi V; Whitney G; Hamid O; Schmidt H; Chasalow SD; Alaparthy S; Jackson JR
    Cancer Immunol Immunother; 2012 May; 61(5):733-7. PubMed ID: 22382362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular-target therapy for advanced malignant melanoma].
    Takahashi S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):19-25. PubMed ID: 23306915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
    Ascierto PA; Agarwala SS; Ciliberto G; Demaria S; Dummer R; Duong CPM; Ferrone S; Formenti SC; Garbe C; Halaban R; Khleif S; Luke JJ; Mir LM; Overwijk WW; Postow M; Puzanov I; Sondel P; Taube JM; Thor Straten P; Stroncek DF; Wargo JA; Zarour H; Thurin M
    J Transl Med; 2017 Nov; 15(1):236. PubMed ID: 29145885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in immunotherapy for melanoma.
    Redman JM; Gibney GT; Atkins MB
    BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained clinico-radiologic response to anti-cytotoxic T lymphocyte antigen 4 antibody therapy in metastatic myxoid liposarcoma.
    Dasanu CA
    J Oncol Pharm Pract; 2017 Oct; 23(7):549-551. PubMed ID: 27511215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for malignant melanoma.
    Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
    Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenging resistance mechanisms to therapies for metastatic melanoma.
    Tentori L; Lacal PM; Graziani G
    Trends Pharmacol Sci; 2013 Dec; 34(12):656-66. PubMed ID: 24210882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nivolumab in melanoma: latest evidence and clinical potential.
    Johnson DB; Peng C; Sosman JA
    Ther Adv Med Oncol; 2015 Mar; 7(2):97-106. PubMed ID: 25755682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
    Koppolu V; Rekha Vasigala VK
    J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antibody therapies for melanoma].
    Kiniwa Y; Okuyama R
    Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
    Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
    J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.